Should You Buy Novo Nordisk Right Now?

Novo Nordisk (NVO) is experiencing divided analyst sentiment, with Morgan Stanley downgrading due to Wegovy's market share loss to Eli Lilly's Zepbound, while HSBC upgraded on pipeline potential. Despite a nearly 50% stock decline reflecting this disappointment, NVO presents a speculative buy opportunity driven by several near-term catalysts. These include an anticipated FDA decision this year for its potentially superior oral weight loss pill, the mid-January completion of a Phase 3 trial for its next-generation weight loss drug CagriSema, and upcoming late 2025/early 2026 results for semaglutide in Alzheimer's, all offering significant upside potential despite acknowledged risks.

Analysis

Novo Nordisk (NVO) is currently experiencing divergent analyst sentiment, with Morgan Stanley downgrading to underweight due to disappointing U.S. prescription growth and market share loss of Wegovy to Eli Lilly's Zepbound. Conversely, HSBC Holdings has upgraded NVO to a buy, citing strong pipeline potential. This market disappointment is reflected in a nearly 50% decline in NVO shares.

Despite these headwinds, NVO possesses several significant near-term catalysts that could re-rate the stock. The company anticipates an FDA decision this year for its oral weight loss pill (oral Wegovy), with data suggesting potential superiority over Eli Lilly's orforglipron. Additionally, the Phase 3 trial (REDEFINE 4) for its next-generation weight loss drug, CagriSema, against Eli Lilly's tirzepatide is set for completion in mid-January.

Further upside potential exists with the expected late 2025 or early 2026 release of Phase 3 trial results for semaglutide in Alzheimer's patients, aiming to slow cognitive decline. However, investors should note prior efficacy disappointments for CagriSema and an executive's characterization of the Alzheimer's trial as a "lottery," indicating inherent risks. The overall sentiment for NVO is moderately positive but speculative, given these high-impact potential events.

Key Decisions for Investors

• Investors should consider Novo Nordisk (NVO) as a speculative buy, weighing the significant upside potential from its pipeline against recent market share losses and share price decline.
• Closely monitor the anticipated FDA decision for NVO's oral weight loss pill this year and the mid-January completion of the CagriSema Phase 3 trial, as these are critical near-term catalysts.
• Assess the company's risk-reward profile, acknowledging the inherent uncertainties in drug development, including prior efficacy concerns for CagriSema and the "lottery" nature of the Alzheimer's trial.